Cis-13-PGD1 compounds

ABSTRACT

Prostaglandin analogs with the following cyclopentane ring structure: ##STR1## are disclosed along with intermediates useful in their preparation and processes for their preparation. These analogs are useful for the same pharmacological purposes as the prostaglandins, particularly and especially as blood platelet aggregation inhibitors.

The present application is a divisional application of Ser. No. 614,242,filed Sept. 17, 1975, now issued as U.S. Pat. No. 4,016,184, on Apr. 5,1977.

The present invention relates to prostaglandin analogs for which theessential material constituting a disclosure therefor is incorporated byreference here from U.S. Pat. No. 4,016,184, issued Apr. 5, 1977.

I claim:
 1. A prostaglandin analog of the formula ##STR2## wherein m isone to 5, inclusive; WHEREIN M₁ is ##STR3## or ##STR4## wherein R₅ andR₆ are hydrogen or methyl, with the proviso that one of R₅ and R₆ ismethyl only when the other is hydrogen;Wherein L₁ is ##STR5## or amixture of ##STR6## and ##STR7## wherein R₃ and R₄ are hydrogen, methyl,or fluoro, being the same or different, with the proviso that one of R₃and R₄ is fluoro only when the other is hydrogen or fluoro; Wherein R₁is hydrogen, alkyl of one of 12 carbon atoms, inclusive, cycloalkyl of 3to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms,inclusive, phenyl, phenyl substituted with one, two, or three chloro oralkyl of one to 3 carbon atoms, inclusive, or a pharmacologicallyacceptable cation; andWherein Z₇ is; (1) --(CH₂)₃ --(CH₂)_(g) --CF₂ --,or (2) --(CH₂)₃ --(CH₂)_(g) --CH₂ --,wherein g is one, 2, or
 3. 2. Acompound according to claim 1, wherein M₁ is ##STR8##
 3. A compoundaccording to claim 1, wherein M₁ is ##STR9## PG,5
 4. A compoundaccording to claim 3, wherein m is
 3. 5. A compound according to claim4, wherein g is
 3. 6. 2a,2b-Dihomo-15-epi-cis-13-PGD₁, a compoundaccording to claim
 5. 7. A compound according to claim 4, wherein g isone.
 8. 15-Epi-cis-13-PGD₁, a compound according to claim
 7. 9.2,2-Difluoro-15-epi-cis-13-PGD₁, a compound according to claim 7.